Amundi
CRNX icon

Amundi’s Crinetics Pharmaceuticals CRNX Stock Holding History

Amundi’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$473K Buy
13,034
+7,412
+132% +$331K ﹤0.01% 1565
2025
Q4 		$262K Buy
+5,622
New +$250K ﹤0.01% 1685
2025
Q2 		– Sell
-57
Closed -$1.65K – 1784
2025
Q1 		$1.65K Buy
57
+5
+10% +$187 ﹤0.01% 1978
2024
Q4 		$2.52K Buy
+52
New +$2.91K ﹤0.01% 1976
2024
Q2 		– Sell
-3,352
Closed -$144K – 1941
2024
Q1 		$144K Hold
3,352
– – ﹤0.01% 1699
2023
Q4 		$127K Buy
3,352
+1,532
+84% +$47K ﹤0.01% 1724
2023
Q3 		$53K Hold
1,820
– – ﹤0.01% 1867
2023
Q2 		$32.8K Sell
1,820
-1,475
-45% -$29.4K ﹤0.01% 1933
2023
Q1 		$52.6K Hold
3,295
– – ﹤0.01% 1878
2022
Q4 		$54.9K Hold
3,295
– – ﹤0.01% 1690
2022
Q3 		$61K Buy
+3,295
New +$67.2K ﹤0.01% 1636

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Amundi's CRNX Position: Q1 2026 in Review

Amundi increased its Crinetics Pharmaceuticals (CRNX) stake by 132% in Q1 2026, buying an estimated $331K and bringing the position to 13,034 shares worth $473K. The position accounts for ﹤0.01% of the portfolio, ranked #1565.

Amundi first reported a position in CRNX in Q3 2022 and has held it in 11 quarters since. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Amundi held 13,034 shares of Crinetics Pharmaceuticals worth $473K as of Q1 2026.
  • Amundi bought 7,412 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $331K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Amundi's portfolio in Q1 2026, its #1565 holding.
  • Amundi first reported a position in Crinetics Pharmaceuticals in Q3 2022 and has held it in 11 quarters since.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Amundi's 13F filing for Q1 2026, filed 18 May 2026.